GlaxoSmithKline expands Fabry disease deal with Amicus, upping stake in the firm
05:57 EDT 19 Jul 2012 | thePharmaLetter
Moving forward with its foray into the rare disease sector, UK pharma giant GlaxoSmithKline (LSE: GSK) and USA-based biotech firm Amicus Therapeutics (Nasdaq: FOLD) expanded their collaboration to develop and commercialize the investigational pharmac..
Original Article: GlaxoSmithKline expands Fabry disease deal with Amicus, upping stake in the firm
More From BioPortfolio on "GlaxoSmithKline expands Fabry disease deal with Amicus, upping stake in the firm"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
